Terms: = Prostate cancer AND CTNNB1, P35222, 1499, ENSG00000168036, CTNNB AND Treatment
24 results:
1. Investigation of iso-propylchaetominine anticancer activity on apoptosis, cell cycle and Wnt signaling pathway in different cancer models.
Karamad V; Sogutlu F; Ozkaya FC; Shademan B; Ebrahim W; El-Neketi M; Avci CB
Fitoterapia; 2024 Mar; 173():105789. PubMed ID: 38158162
[TBL] [Abstract] [Full Text] [Related]
2. Mutations in epigenetic regulator
Zhu S; Xu N; Liang J; Zhao F; Wang Z; Ni Y; Dai J; Zhao J; Zhang X; Chen J; Sun G; Shen P; Zeng H
Oncol Res; 2023; 31(4):605-614. PubMed ID: 37415738
[TBL] [Abstract] [Full Text] [Related]
3. RBM3 suppresses stemness remodeling of prostate cancer in bone microenvironment by modulating N6-methyladenosine on ctnnb1 mRNA.
Zhang S; Lv C; Niu Y; Li C; Li X; Shang Y; Zhang Y; Zhang Y; Zhang Y; Zeng Y
Cell Death Dis; 2023 Feb; 14(2):91. PubMed ID: 36750551
[TBL] [Abstract] [Full Text] [Related]
4. WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive prostate cancer.
Sutera P; Deek MP; Van der Eecken K; Shetty AC; Chang JH; Hodges T; Song Y; Verbeke S; Van Dorpe J; Fonteyne V; De Laere B; Mishra M; Rana Z; Molitoris J; Ferris M; Ross A; Schaeffer E; Roberts N; Song DY; DeWeese T; Pienta KJ; Antonarakis ES; Ost P; Tran PT
Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1095-1101. PubMed ID: 36708787
[TBL] [Abstract] [Full Text] [Related]
5. FLG Gene Mutation Up-regulates the Abnormal Tumor Immune Response and Promotes the Progression of prostate cancer.
Zhang P; An Z; Sun C; Xu Y; Zhang Z
Curr Pharm Biotechnol; 2022; 23(14):1658-1670. PubMed ID: 35422210
[TBL] [Abstract] [Full Text] [Related]
6. Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant prostate cancer.
Ma F; Arai S; Wang K; Calagua C; Yuan AR; Poluben L; Gu Z; Russo JW; Einstein DJ; Ye H; He MX; Liu Y; Van Allen E; Sowalsky AG; Bhasin MK; Yuan X; Balk SP
Cancer Res; 2022 Apr; 82(8):1518-1533. PubMed ID: 35131873
[TBL] [Abstract] [Full Text] [Related]
7. Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive prostate cancer: A Systematic Review.
Van der Eecken K; Vanwelkenhuyzen J; Deek MP; Tran PT; Warner E; Wyatt AW; Kwan EM; Verbeke S; Van Dorpe J; Fonteyne V; Lumen N; De Laere B; Ost P
Eur Urol Oncol; 2021 Dec; 4(6):914-923. PubMed ID: 34801437
[TBL] [Abstract] [Full Text] [Related]
8. Clinical and genomic features of SPOP-mutant prostate cancer.
Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
[TBL] [Abstract] [Full Text] [Related]
9. In-silico identification of frequently mutated genes and their co-enriched metabolic pathways associated with prostate cancer progression.
Singh AN; Sharma N
Andrologia; 2021 Dec; 53(11):e14236. PubMed ID: 34468989
[TBL] [Abstract] [Full Text] [Related]
10. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
[TBL] [Abstract] [Full Text] [Related]
11. Identification of key genes and pathways in IgA nephropathy using bioinformatics analysis.
Hu SL; Wang D; Yuan FL; Lei QF; Zhang Y; Cheng JZ
Medicine (Baltimore); 2020 Jul; 99(30):e21372. PubMed ID: 32791747
[TBL] [Abstract] [Full Text] [Related]
12. An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic prostate cancer.
Dawson NA; Zibelman M; Lindsay T; Feldman RA; Saul M; Gatalica Z; Korn WM; Heath EI
Mol Cancer Ther; 2020 Jun; 19(6):1373-1382. PubMed ID: 32220973
[TBL] [Abstract] [Full Text] [Related]
13. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant prostate cancer.
Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
[TBL] [Abstract] [Full Text] [Related]
14. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review).
Katoh M
Int J Mol Med; 2018 Aug; 42(2):713-725. PubMed ID: 29786110
[TBL] [Abstract] [Full Text] [Related]
15. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk prostate cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.
Michalski JM; Moughan J; Purdy J; Bosch W; Bruner DW; Bahary JP; Lau H; Duclos M; Parliament M; Morton G; Hamstra D; Seider M; Lock MI; Patel M; Gay H; Vigneault E; Winter K; Sandler H
JAMA Oncol; 2018 Jun; 4(6):e180039. PubMed ID: 29543933
[TBL] [Abstract] [Full Text] [Related]
16. Molecular genetics and targeted therapy of WNT-related human diseases (Review).
Katoh M; Katoh M
Int J Mol Med; 2017 Sep; 40(3):587-606. PubMed ID: 28731148
[TBL] [Abstract] [Full Text] [Related]
17. CAPE suppresses migration and invasion of prostate cancer cells via activation of non-canonical Wnt signaling.
Tseng JC; Lin CY; Su LC; Fu HH; Yang SD; Chuu CP
Oncotarget; 2016 Jun; 7(25):38010-38024. PubMed ID: 27191743
[TBL] [Abstract] [Full Text] [Related]
18. Physical Activity and cancer Outcomes: A Precision Medicine Approach.
Friedenreich CM; Neilson HK; Farris MS; Courneya KS
Clin Cancer Res; 2016 Oct; 22(19):4766-4775. PubMed ID: 27407093
[TBL] [Abstract] [Full Text] [Related]
19. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant prostate cancer.
Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
[TBL] [Abstract] [Full Text] [Related]
20. CYP1B1 Enhances Cell Proliferation and Metastasis through Induction of EMT and Activation of Wnt/β-Catenin Signaling via Sp1 Upregulation.
Kwon YJ; Baek HS; Ye DJ; Shin S; Kim D; Chun YJ
PLoS One; 2016; 11(3):e0151598. PubMed ID: 26981862
[TBL] [Abstract] [Full Text] [Related]
[Next]
